Hua Medicine (Shanghai) Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMDF research report →
About the company
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D).
- CEO
- Li Chen
- IPO
- 2021
- Employees
- 168
- HQ
- Shanghai, CN
Price Chart
- Market Cap
- $338.92M
- P/E
- 2.12
- P/S
- 4.54
- P/B
- 2.33
- EV/EBITDA
- -11.76
- Div Yield
- 0.00%
- Gross Margin
- 56.85%
- Op Margin
- -29.40%
- Net Margin
- 226.82%
- ROE
- 107.22%
- ROIC
- -10.97%
- Revenue
- $480.21M · 87.66%
- Net Income
- $1.08B · 530.87%
- EPS
- $1.12 · 548.00%
- Op Income
- $-141,143,190
- FCF YoY
- 85.85%
- 52W High
- $0.50
- 52W Low
- $0.34
- 50D MA
- $0.41
- 200D MA
- $0.41
- Beta
- 0.80
- Avg Volume
- 322
Get TickerSpark's AI analysis on HUMDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HUMDF coverage
Recent articles, reports, and earnings notes.
No research on HUMDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HUMDF report →Similar companies
Peers in the same neighborhood.